Examination of tissue penetration of garenoxacin (GRNX) for peritonsillar abscess

Examination of tissue penetration of garenoxacin (GRNX) for peritonsillar abscess - Examination of tissue penetration of garenoxacin (GRNX) for peritonsillar abscess

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000014258

Enrollment

Registered

2014-06-13

Start date

2013-07-17

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

peritonsillar abscess

Interventions

Period until March 31, 2015 from a clinical study approval date. For patients over the age of 20, garenoxacin performing oral administration of 400mg. Evaluated is scheduled for 20 cases.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: For the treatment of peritonsillar abscess, orally ingestible the garenoxacin (GRNX), patients over 20 years old that underwent abscess tonsillectomy.

Exclusion criteria

Exclusion criteria: Case can not be obtained consent to participate in this study excluded.

Design outcomes

Primary

Measure	Time frame
Target patients over 20 years old who immediately abscess tonsillectomy for the treatment of peritonsillar abscess. In patients who ingest the GRNX, tonsil tissue taken at the time of surgery, pus, each serum, to measure the concentration of GRNX. Target number of cases to 20 cases.	—

Countries

Japan

Contacts

Public ContactKeiichi Miyashita

Kagoshima University Graduate School of Medical and Dental Sciences Department of Otolaryngology, Head and Neck Surgery

entjm@m.kagoshima-u.ac.jp099-275-5410

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026